These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31967783)

  • 21. Improving the drug-likeness of inspiring natural products - evaluation of the antiparasitic activity against Trypanosoma cruzi through semi-synthetic and simplified analogues of licarin A.
    Morais TR; Conserva GAA; Varela MT; Costa-Silva TA; Thevenard F; Ponci V; Fortuna A; Falcão AC; Tempone AG; Fernandes JPS; Lago JHG
    Sci Rep; 2020 Mar; 10(1):5467. PubMed ID: 32214193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Discovery for Paediatric Chagas Disease.
    Thota S; Morel CM
    Mini Rev Med Chem; 2018; 18(9):776-780. PubMed ID: 26202205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani.
    Corpas-Lopez V; Moniz S; Thomas M; Wall RJ; Torrie LS; Zander-Dinse D; Tinti M; Brand S; Stojanovski L; Manthri S; Hallyburton I; Zuccotto F; Wyatt PG; De Rycker M; Horn D; Ferguson MAJ; Clos J; Read KD; Fairlamb AH; Gilbert IH; Wyllie S
    ACS Infect Dis; 2019 Jan; 5(1):111-122. PubMed ID: 30380837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abietane-Type Diterpenoid Amides with Highly Potent and Selective Activity against Leishmania donovani and Trypanosoma cruzi.
    Pirttimaa M; Nasereddin A; Kopelyanskiy D; Kaiser M; Yli-Kauhaluoma J; Oksman-Caldentey KM; Brun R; Jaffe CL; Moreira VM; Alakurtti S
    J Nat Prod; 2016 Feb; 79(2):362-8. PubMed ID: 26849852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the antiparasitic and anticancer activity of the coconut palm (Cocos nucifera L. ARECACEAE) from the natural reserve of Punta Patiño, Darién.
    Tayler NM; Boya CA; Herrera L; Moy J; Ng M; Pineda L; Almanza A; Rosero S; Coronado LM; Correa R; Santamaría R; Caballero Z; Durant-Archibold AA; Tidgewell KJ; Balunas MJ; Gerwick WH; Spadafora A; Gutiérrez M; Spadafora C
    PLoS One; 2019; 14(4):e0214193. PubMed ID: 30939131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A promising pipeline of preclinical drug candidates for leishmaniasis and chronic Chagas' disease.
    Saldivia M; Lima APCA; Mottram JC
    Trends Parasitol; 2024 Mar; 40(3):211-213. PubMed ID: 38368155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation, Derivative Synthesis, and Structure-Activity Relationships of Antiparasitic Bromopyrrole Alkaloids from the Marine Sponge Tedania brasiliensis.
    Parra LLL; Bertonha AF; Severo IRM; Aguiar ACC; de Souza GE; Oliva G; Guido RVC; Grazzia N; Costa TR; Miguel DC; Gadelha FR; Ferreira AG; Hajdu E; Romo D; Berlinck RGS
    J Nat Prod; 2018 Jan; 81(1):188-202. PubMed ID: 29297684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani.
    Chibale K; Visser M; Yardley V; Croft SL; Fairlamb AH
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1147-50. PubMed ID: 10866368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The uniqueness of the Trypanosoma cruzi mitochondrion: opportunities to identify new drug target for the treatment of Chagas disease.
    Lisvane Silva P; Mantilla BS; Barisón MJ; Wrenger C; Silber AM
    Curr Pharm Des; 2011; 17(20):2074-99. PubMed ID: 21718252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery.
    Ekins S; de Siqueira-Neto JL; McCall LI; Sarker M; Yadav M; Ponder EL; Kallel EA; Kellar D; Chen S; Arkin M; Bunin BA; McKerrow JH; Talcott C
    PLoS Negl Trop Dis; 2015; 9(6):e0003878. PubMed ID: 26114876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiparasitic activities of novel pyrimidine N-acylhydrazone hybrids.
    Poletto J; da Silva MJV; Jacomini AP; Bidóia DL; Volpato H; Nakamura CV; Rosa FA
    Drug Dev Res; 2021 Apr; 82(2):230-240. PubMed ID: 32996619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
    Papadopoulou MV; Bloomer WD; Rosenzweig HS; Wilkinson SR; Kaiser M
    Eur J Med Chem; 2014 Nov; 87():79-88. PubMed ID: 25240098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani.
    McNamara N; Saunders E; Varghese S; Zheng R; Simpson K; Varma DM; Johnson MM; Hasan Zahid MS; Bachelder EM; Ainslie KM; No JH; Koh D; Shum D; Das N; Patra B; Roy J; Talukdar A; Ganguly D; McConville M; Baell J
    Eur J Med Chem; 2022 Oct; 240():114577. PubMed ID: 35810535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
    Saccoliti F; Madia VN; Tudino V; De Leo A; Pescatori L; Messore A; De Vita D; Scipione L; Brun R; Kaiser M; Mäser P; Calvet CM; Jennings GK; Podust LM; Costi R; Di Santo R
    Eur J Med Chem; 2018 Aug; 156():53-60. PubMed ID: 30006174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tropical and Subtropical Parasitic Diseases: Targets for a New Approach to Virtual Screening.
    Yunta MJR; Dietrich RC
    Mol Inform; 2019 Nov; 38(11-12):e1900052. PubMed ID: 31490642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human mixed infections of Leishmania spp. and Leishmania-Trypanosoma cruzi in a sub Andean Bolivian area: identification by polymerase chain reaction/hybridization and isoenzyme.
    Bastrenta B; Mita N; Buitrago R; Vargas F; Flores M; Machane M; Yacsik N; Torrez M; Le Pont F; Brenière F
    Mem Inst Oswaldo Cruz; 2003 Mar; 98(2):255-64. PubMed ID: 12764443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Squalamine analogues as potential anti-trypanosomal and anti-leishmanial compounds.
    Khabnadideh S; Tan CL; Croft SL; Kendrick H; Yardley V; Gilbert IH
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1237-9. PubMed ID: 10866389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of agelasine D and analogs for inhibitory activity against pathogenic protozoa; identification of hits for visceral leishmaniasis and Chagas disease.
    Vik A; Proszenyák A; Vermeersch M; Cos P; Maes L; Gundersen LL
    Molecules; 2009 Jan; 14(1):279-88. PubMed ID: 19136916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro action of platinum (II) and platinum (IV) complexes on Trypanosoma cruzi and Leishmania donovani.
    Mesa-Valle CM; Craciunescu D; Parrondo-Iglesias E; Osuna A
    Arzneimittelforschung; 1989 Aug; 39(8):838-42. PubMed ID: 2684173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.